

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (withdrawn-currently amended) [[A]] An isolated biopolymer marker consisting of SEQ ID NO:1 having a sequence identified as SEQ ID NO:1 useful in indicating at least one particular disease state which evidences a link to myocardial infarction.

Claims 2-35. (cancelled)

Claim 36. (new) A method for determining the presence of a biopolymer marker consisting of SEQ ID NO:1 comprising:

- (a) obtaining a sample from a patient;
- (b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said biopolymer marker consisting of SEQ ID NO:1 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

(c) confirming the presence of said biopolymer marker consisting of SEQ ID NO:1 is said sample displaying a peak profile at about 1562 daltons in said mass spectrum profile;

wherein the presence of said biopolymer marker consisting of SEQ ID NO:1 is indicative of a link to myocardial infarction.

Claim 37. (new) The method of claim 36, wherein said sample is an unfractionated body fluid or a tissue sample.

Claim 38. (new) The method of claim 36, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 39. (new) The method of claim 36, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claim 40. (new) The method of claim 36, wherein said patient is a human.

Claim 41. (new) A kit for determining the presence of a biopolymer marker consisting of SEQ ID NO:1 comprising: (a) a peptide consisting of SEQ ID NO:1, and (b) an antibody that binds to said peptide in a sample from a patient.

Claim 42. (new) The kit of claim 41, wherein said antibody is immobilized on a solid support.

Claim 43. (new) The kit of claim 41, wherein said antibody is labeled.